Publications by authors named "Xiao Li Wei"

Article Synopsis
  • There is a clinical need to improve the effectiveness and safety of current anti-PD-1/PD-L1 cancer immunotherapy, leading to the study of IBI318, a novel bispecific antibody targeting PD-1 and PD-L1 in patients with advanced tumors.
  • The clinical trial consisted of two phases: Phase Ia focused on dose escalation to find the optimal dosage, while Phase Ib evaluated safety and efficacy in patients with non-small cell lung cancer and nasopharyngeal carcinoma.
  • Results showed that IBI318 had a good safety profile with an objective response rate of 15.5% overall, and higher rates in treatment-naïve patients: 45.5% for NSCLC and 30.0% for
View Article and Find Full Text PDF

This study extensively explored the adsorption behavior of heavy metals (Pb, Ni, Cu, Zn, and Cd) onto microplastics (MPs). The particle sizes of MPs ranged from 0.149 to 0.

View Article and Find Full Text PDF

Objective: The purpose of this study was to three-dimensionally evaluate the relationship between the degree of bilateral impacted mandibular third molar (IM3M) angulation and the mandibular dental arch parameters in normal skeletal and dental malocclusion patients.

Materials And Methods: In this retrospective cross-sectional comparative study, 120 adult subjects' cone-beam computed tomography (CBCT) images were three-dimensionally analyzed. The sample included 120 adults aged 20-30 years, with a gender distribution of 51 male and 69 female participants.

View Article and Find Full Text PDF
Article Synopsis
  • * Mesaconine, a key component of Fuzi, shows promise in reversing cardiac dysfunction caused by doxorubicin (DOX) treatment by restoring proper mitophagy in heart cells.
  • * The cardioprotective effects of mesaconine are mainly linked to its ability to enhance PINK1-mediated mitophagy, suggesting it could be a potential therapy for heart failure.
View Article and Find Full Text PDF

Background: Epstein-Barr virus-associated gastric cancer (EBVaGC) exhibits unique histological characteristics within the immune-cell-rich microenvironment, but the role of tertiary lymphoid structure (TLS) in EBVaGC is not yet fully understood.

Methods: We retrospectively identified EBVaGC from 8517 consecutive GC cases from the two top cancer centers in China. Furthermore, we evaluated the prognostic value of TLS in 148 EBVaGC patients from our institute and then validated it in an external cohort (76 patients).

View Article and Find Full Text PDF

Background: SHR7390 is a novel, selective MEK1/2 inhibitor. Here, we report results from two phase I trials conducted to evaluate the tolerability, safety and antitumor activity of SHR7390 monotherapy for advanced solid tumors and SHR7390 plus camrelizumab for treatment-refractory advanced or metastatic colorectal cancer (CRC).

Patients And Methods: Patients received SHR7390 alone or combined with fixed-dose camrelizumab (200 mg every 2 weeks) in an accelerated titration scheme to determine the maximum tolerated dose (MTD).

View Article and Find Full Text PDF
Article Synopsis
  • PIK3CA mutations are common in solid tumors, making PI3Kα a promising target for cancer treatment.
  • A study tested CYH33, a selective PI3Kα inhibitor, on 51 patients with advanced solid tumors, focusing on safety, maximum tolerated dose, and preliminary efficacy.
  • Results showed a maximum tolerated dose of 40 mg daily, manageable side effects, and a preliminary objective response rate of 14.3% in patients with PIK3CA mutations, suggesting potential effectiveness of CYH33.
View Article and Find Full Text PDF

ARX788 is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate with AS269 as cytotoxic payload. In this phase 1 multicenter dose-expansion clinical trial, patients with HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma failing to respond to prior trastuzumab-based standard treatment were enrolled. Between July 15, 2019, and March 14, 2022, 30 participants were enrolled.

View Article and Find Full Text PDF

To further reveal the active ingredients of Danshen, we systematically studied its chemical components and obtained two new lithospermic acid derivatives (compounds 1 and 2) together with five known phenylpropionic acids (compounds 3-7) from the dried rhizomes of Salvia miltiorrhiza. The structures of the two new compounds were determined by multiple spectral analyses (UV, IR, HR-ESI-MS, NMR, and ECD). In addition, the absolute configurations were established by chiral analysis and calculated and experimental circular dichroism spectra.

View Article and Find Full Text PDF

The general immune landscape of nasopharyngeal carcinoma (NPC) renders immunotherapy suitable for patients with NPC. Immune checkpoint inhibitors (ICIs) based on programmed death-1/programmed death ligand-1 (PD-1/PD-L1) blockade have made a breakthrough with the approval of PD-1 inhibitor for refractory recurrence and/or metastatic (R/M NPC) and the approval of PD-1 inhibitor in combination with gemcitabine and cisplatin as first line for R/M NPC in 2021 in China. The incorporation of ICIs into the treatment paradigms of NPC has become a clinical hot spot and many prospective clinical studies are ongoing.

View Article and Find Full Text PDF

Background: Pancreatic acinar cell carcinoma (PACC) is rare, and its appropriate treatment remains unknown. We aim to explore the characteristics and optimal treatment of it.

Methods: The data on clinicopathologic characteristics, molecular alteration, treatment, and survival of patients diagnosed with PACC at the Sun Yat-sen University Cancer Center from 2005 to 2020 were collected.

View Article and Find Full Text PDF
Article Synopsis
  • Anti-PD-1 immunotherapy shows improved survival in some patients with recurrent metastatic nasopharyngeal carcinoma (RM-NPC), but the role of plasma EBV DNA titers in predicting outcomes is still unclear.
  • A study evaluated the association of plasma EBV DNA levels in prognostic predictions and monitoring progression in RM-NPC patients receiving anti-PD-1 therapy.
  • Results indicated that higher baseline EBV DNA levels correlated with shorter overall survival, particularly in patients whose EBV titers decreased significantly by week 4 of treatment.
View Article and Find Full Text PDF

Nuclear receptor corepressor 1 (NCoR1) is a corepressor of the epigenetic regulation of gene transcription that has important functions in metabolism and inflammation, but little is known about its role in alcohol-associated liver disease (ALD). In this study, we developed mice with hepatocyte-specific NCoR1 knockout (NCoR1) using the albumin-Cre/LoxP system and investigated the role of NCoR1 in the pathogenesis of ALD and the underlying mechanisms. The traditional alcohol feeding model and NIAAA model of ALD were both established in wild-type and NCoR1 mice.

View Article and Find Full Text PDF

Cetuximab is one of the most widely used monoclonal antibodies to treat patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC). Unfortunately, cetuximab resistance often occurs during targeted therapy. However, the underlying epigenetic mechanisms remain unclear.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on identifying predictive biomarkers for the effectiveness of anti-PD-1 monoclonal antibody treatment in advanced gastric cancer (AGC) patients, given its limited efficacy for some individuals.
  • Researchers analyzed data from 58 chemorefractory AGC patients, measuring treatment outcomes and examining immune cell presence in tumor tissues through transcriptome sequencing.
  • Results indicated that higher baseline blood neutrophil-to-lymphocyte ratio (bNLR) and its early changes (dNLR) were linked to poorer survival rates and treatment responses, highlighting their potential use as prognostic indicators in clinical settings.
View Article and Find Full Text PDF

HDAC inhibitors (HDACis) have been intensively studied for their roles and potential as drug targets in T-cell lymphomas and other hematologic malignancies. Bisthianostat is a novel bisthiazole-based pan-HDACi evolved from natural HDACi largazole. Here, we report the preclinical study of bisthianostat alone and in combination with bortezomib in the treatment of multiple myeloma (MM), as well as preliminary first-in-human findings from an ongoing phase 1a study.

View Article and Find Full Text PDF

Dysregulation of lipid metabolism plays important roles in the tumorigenesis and progression of gastric cancer (GC). The present study aimed to establish a prognostic model based on the lipid metabolism-related genes in GC patients. Two GC datasets from the Gene Expression Atlas, GSE62254 ( = 300) and GSE26942 ( = 217), were used as training and validation cohorts to establish a risk predictive scoring model.

View Article and Find Full Text PDF

The effect of anti-programmed cell death 1 (PD-1) antibody in Epstein-Barr virus-associated gastric cancer (EBVaGC) was debatable, and no predictive biomarkers for efficacy have been reported. Public reports on anti-PD-1 antibody monotherapy-treated EBVaGC with available programmed death ligand-1 (PD-L1) expression status were summarized and analyzed. Relevance with clinicopathologic characteristics of PD-L1 expression by immunohistochemistry was analyzed in 159 patients diagnosed with EBVaGC.

View Article and Find Full Text PDF

Acephalic spermatozoa syndrome is a rare type of teratozoospermia that severely impairs the reproductive ability of male patients, and genetic defects have been recognized as the main cause of acephalic spermatozoa syndrome. Spermatogenesis and centriole-associated 1 like (SPATC1L) is indispensable for maintaining the integrity of sperm head-to-tail connections in mice, but its roles in human sperm and early embryonic development remain largely unknown. Herein, we conducted whole-exome sequencing (WES) of 22 infertile men with acephalic spermatozoa syndrome.

View Article and Find Full Text PDF

Accurate survival prediction of persons with plasma cell myeloma (PCM) is challenging. We interrogated clinical and laboratory co-variates and RNA matrices of 1040 subjects with PCM from public datasets in the Gene Expression Omnibus database in training (N = 1) and validation (N = 2) datasets. Genes regulating plasma cell metabolism correlated with survival were identified and seven used to build a metabolic risk score using Lasso Cox regression analyses.

View Article and Find Full Text PDF

Background: We previously reported tumor mutation burden (TMB) as a potential prognostic factor for patients with advanced gastric cancer (AGC) receiving immunotherapy. We aimed to comprehensively understand the impact of tumor burden and TMB on efficacy and prognosis in immunotherapy-treated AGC patients.

Methods: A total of 58 patients with refractory AGC receiving PD-1 inhibitor monotherapy from a phase Ib/II clinical trial (ClinicalTrials.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated toripalimab, a new PD-1 inhibitor, for treating patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who didn't respond to standard chemotherapy.
  • Among the 190 patients treated, the overall response rate (ORR) was 20.5%, with a median duration of response of 12.8 months and overall survival of 17.4 months.
  • A significant correlation was found between a decrease in plasma EBV DNA after 28 days and better treatment response, while genomic alterations were linked to poorer outcomes.
View Article and Find Full Text PDF

Background: The outcomes of immune checkpoint inhibitors in cancer patients with liver metastases are poor, which may be related to a different tumor microenvironment in liver metastases from primary tumors. This study was aimed to analyze PD-L1 expression and the immune microenvironment status in liver metastases and compare the differences of PD-L1 expression between primary tumors and liver metastases of colorectal cancer.

Methods: 74 cases of pathologically confirmed colorectal cancer with liver metastasis underwent resection from our hospital were included.

View Article and Find Full Text PDF
Article Synopsis
  • This study explores the effectiveness of anti-PD-1 immune checkpoint blockade in treating oesophageal squamous cell carcinoma (ESCC), emphasizing the need for reliable predictors to identify which patients will respond positively to the therapy.
  • The researchers analyzed biopsy samples and found that the RBPJL protein plays a crucial role in the tumor response to toripalimab, a type of anti-PD-1 therapy, and identified mutations that impacted treatment outcomes.
  • The study concludes that the RBPJL (p.P476S) mutation enhances tumor growth in ESCC and reduces the effectiveness of anti-PD-1 therapy, suggesting that RBPJL could serve as a new marker to predict treatment success.*
View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the safety and effectiveness of toripalimab, an anti-PD-1 antibody, in Chinese patients with advanced malignant tumors, filling a gap in data previously focused on Western populations.
  • The research included a phase I trial with 25 patients, observing common side effects like fatigue and rash, but no serious adverse events or dose-limiting toxicities.
  • Results showed a 12.5% objective response rate, with most patients maintaining high PD-1 receptor occupancy, suggesting toripalimab could be an effective treatment option for difficult-to-treat cancers.
View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: